These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21347617)

  • 21. Anacetrapib as a potential cardioprotective strategy.
    Di Bartolo BA; Nicholls SJ
    Drug Des Devel Ther; 2017; 11():3497-3502. PubMed ID: 29263647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anacetrapib: a potential new therapy for dyslipidemia.
    Robinson LB; Frishman WH
    Cardiol Rev; 2014; 22(5):253-61. PubMed ID: 24618931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Kastelein JJ; Besseling J; Shah S; Bergeron J; Langslet G; Hovingh GK; Al-Saady N; Koeijvoets M; Hunter J; Johnson-Levonas AO; Fable J; Sapre A; Mitchel Y
    Lancet; 2015 May; 385(9983):2153-61. PubMed ID: 25743173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
    Tan EY; Hartmann G; Chen Q; Pereira A; Bradley S; Doss G; Zhang AS; Ho JZ; Braun MP; Dean DC; Tang W; Kumar S
    Drug Metab Dispos; 2010 Mar; 38(3):459-73. PubMed ID: 20016052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbit.
    Wu BJ; Shrestha S; Ong KL; Johns D; Hou L; Barter PJ; Rye KA
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):628-36. PubMed ID: 25633313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Krishna R; Garg A; Jin B; Keshavarz SS; Bieberdorf FA; Chodakewitz J; Wagner JA
    Br J Clin Pharmacol; 2009 May; 67(5):520-6. PubMed ID: 19552746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study.
    Gotto AM; Kher U; Chatterjee MS; Liu Y; Li XS; Vaidya S; Cannon CP; Brinton EA; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P;
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):543-9. PubMed ID: 24737712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects.
    Krishna R; Gheyas F; Corr C; Cote J; Liu Y; Wagner J; Gutstein DE
    J Clin Pharmacol; 2018 Dec; 58(12):1578-1585. PubMed ID: 30029292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
    Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
    Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
    Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of Anacetrapib Distribution into the Lipid Droplet of Adipose Tissue in Mice and Human Cultured Adipocytes.
    Johns DG; LeVoci L; Krsmanovic M; Lu M; Hartmann G; Xu S; Wang SP; Chen Y; Bateman T; Blaustein RO
    Drug Metab Dispos; 2019 Mar; 47(3):227-233. PubMed ID: 30567880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
    Krishna R; Anderson MS; Bergman AJ; Jin B; Fallon M; Cote J; Rosko K; Chavez-Eng C; Lutz R; Bloomfield DM; Gutierrez M; Doherty J; Bieberdorf F; Chodakewitz J; Gottesdiener KM; Wagner JA
    Lancet; 2007 Dec; 370(9603):1907-14. PubMed ID: 18068514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
    ; Bowman L; Hopewell JC; Chen F; Wallendszus K; Stevens W; Collins R; Wiviott SD; Cannon CP; Braunwald E; Sammons E; Landray MJ
    N Engl J Med; 2017 Sep; 377(13):1217-1227. PubMed ID: 28847206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
    Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
    Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.
    Millar JS; Reyes-Soffer G; Jumes P; Dunbar RL; deGoma EM; Baer AL; Karmally W; Donovan DS; Rafeek H; Pollan L; Tohyama J; Johnson-Levonas AO; Wagner JA; Holleran S; Obunike J; Liu Y; Ramakrishnan R; Lassman ME; Gutstein DE; Ginsberg HN; Rader DJ
    J Clin Invest; 2015 Jun; 125(6):2510-22. PubMed ID: 25961461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Krishna R; Garg A; Panebianco D; Cote J; Bergman AJ; Van Hoydonck P; Laethem T; Van Dyck K; Chen J; Chavez-Eng C; Archer L; Lutz R; Hilliard D; Snyder K; Jin B; Van Bortel L; Lasseter KC; Al-Huniti N; Dykstra K; Gottesdiener K; Wagner JA
    Br J Clin Pharmacol; 2009 Oct; 68(4):535-45. PubMed ID: 19843057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case.
    Johns DG; Wang SP; Rosa R; Hubert J; Xu S; Chen Y; Bateman T; Blaustein RO
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00543. PubMed ID: 31832204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Krishna R; Stypinski D; Ali M; Garg A; Cote J; Maes A; Degroot B; Liu Y; Li S; Connolly SM; Wagner JA; Stoch SA
    Br J Clin Pharmacol; 2012 Jul; 74(1):116-24. PubMed ID: 22243494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Ballantyne CM; Shah S; Sapre A; Ashraf TB; Tobias SC; Sahin T; Ye P; Dong Y; Sheu WH; Kang DH; Ferreira Rossi PR; Moiseeva Y; Briones IR; Johnson-Levonas AO; Mitchel YB
    Am J Cardiol; 2017 Aug; 120(4):569-576. PubMed ID: 28624096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anacetrapib: a new weapon against dyslipidemia.
    Aperis G; Paliouras C; Tsampikaki E; Papakonstantinou N; Alivanis P
    Curr Clin Pharmacol; 2011 Nov; 6(4):227-35. PubMed ID: 22082322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.